LKT Labs

Biochemicals for Life Science Research

Dabrafenib

Dabrafenib

Product ID D0004
Cas No. 1195765-45-7
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $55.10 In stock
25 mg $148.90 In stock
100 mg $529.20 In stock
Bulk Quote

Quicklinks

Description

Dabrafenib is a reversible kinase inhibitor with anticancer chemotherapeutic activity. This compound is selective primarily for mutant (V600E) B-Raf, but has also inhibited tumor growth in cells expressing other B-Raf mutants (V600K, V600D) and WT B-Raf. Dabrafenib is partially active against c-Raf as well. Dabrafenib is an ATP-competitive inhibitor that has been approved for clinical use in the treatment of unresectable or metastatic melanomas; it is also being examined for treatment of brain metastases and other cancers. This compound has a very high oral bioavailability.

Product Info

Cas No.

1195765-45-7
Purity

≥98%
Formula

C23H20F3N5O2S2
Formula Wt.

519.56
IUPAC Name

N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1, 3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
Synonym

GSK2118436A
Solubility

soluble in DSMO
Appearance

White Crystal Powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

D0004 MSDS PDF
Info Sheet

D0004 Info Sheet PDF
Brochures

Ras-Raf-MEK-ERK Pathway Booklet

References

Ballantyne AD, Garnock-Jones KP. Dabrafenib: First Global Approval. Drugs. 2013 Jul 24. [Epub ahead of print] PMID: 23881668.

Huang T, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 25;6:30. PMID: 23617957.

Klinac D, Gray ES, Millward M, et al. Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol. 2013;3:54. PMID: 23515890.

Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358-65. PMID: 22735384.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • C0271

    Carfilzomib

    Epoxomicin analog; proteasome inhibitor.
    ≥98%
  • P1760

    Peptide T

    Peptide fragment of HIV-1 gp120.
    ≥98%
  • G6400

    Glycylglutamine

    Endogenous dipeptide, beta-endorphin derivative.
    ≥95%
  • N0163

    2-(1,8-Naphthyridin-2-yl)phenol

    Naphthalene; indirect STAT1 agonist.
    ≥98%
  • T1673

    Terlipressin Acetate

    Synthetic peptide, vasopressin analog; AVPR1 agoni...
    ≥95%
  • B6805

    Bradykinin (1-7)

    Natriuretic, vasodilatory peptide fragment; B1/2 a...
    ≥95%
  • A0916

    Acepromazine Maleate

    Phenothiazine derivative; D1/2 and 5-HT1A/2A antag...
    ≥98%
  • G7241

    GSK-461364

    PLK1 inhibitor.
    ≥99%
  • C0365

    Carvedilol

    FIASMA; α1- and β1/2-adrenergic antagonist.
    ≥98%
  • W2800

    WH-4-023

    Lck, Src, SIK inhibitor.
    ≥99 %
  • C0265

    Carnosic Acid

    Diterpene found in Rosmarinus.
    ≥98%
  • T5870

    Torin 1

    Tricyclic benzonaphthyridinone; mTORC1/2 inhibitor...
    ≥98%
  • C2997

    Chymostatin

    Protease inhibitor.
    ≥95% (mixture of A, B, C)
  • E6995

    Erythromycin Ethylsuccinate

    Macrolide; protein translation inhibitor, mammalia...
    ≥97%
  • P3576

    Pitavastatin Calcium

    Statin; HMG-CoA reductase inhibitor.
    ≥98%
  • B1603

    Beauvericin

    Cyclic hexadepsipeptide mycotoxin produced by Cord...
    ≥95%
  • J8800

    JW55

    TNKS1/2 inhibitor.
    ≥98%
  • A4646

    ALLN

    Calpain I/II inhibitor.
    ≥98%
  • C9612

    Cyclosporin C

    Cyclosporin metabolite; weak calmodulin inhibitor.
    ≥98%
  • S0254

    Sanguinarine Chloride

    Decreases expression of MMPs, PGE2, and COX-2, and...
    ≥98%